Umoja Biopharma
Louisville, Colorado, United States · Biotechnology, Therapeutics · 191 employees
Umoja Biopharma, Inc. is a clinical-stage biotechnology company aiming to develop off-the-shelf therapeutics that improve the reach, effectiveness, and access of CAR T cell therapies in both oncology and autoimmunity. Umoja’s VivoVec™ in vivo gene delivery technology empowers a patient’s own immune system to fight disease. Enabling its core technology is the Company’s state-of-the-art lentiviral v
Funding history
- Series series c — $100.0M — Jan 2025
- Funding Round — $210.0M — Jun 2021
Recent signals
- Jan 14, 2025: Raised $100.0M in Series series c
- Jan 14, 2025: Umoja Biopharma Announces $100 Million Series C Financing Co-Led by Double Point Ventures and DCVC Bio
- Feb 28, 2024: Umoja Biopharma Announces Appointment of Britton Russell as Chief Financial Officer
- Jun 24, 2021: Raised $210.0M
See plans & pricing → Track Umoja Biopharma’s funding, hiring, and signals — with verified contacts — on Fundz.